Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH. Xu J, et al. Among authors: park sr. Lancet Oncol. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0. Epub 2023 Apr 17. Lancet Oncol. 2023. PMID: 37080222 Clinical Trial.
Management of gastric cancer in Asia: resource-stratified guidelines.
Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Shen L, et al. Among authors: park sr. Lancet Oncol. 2013 Nov;14(12):e535-47. doi: 10.1016/S1470-2045(13)70436-4. Lancet Oncol. 2013. PMID: 24176572 Review.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Noh SH, et al. Among authors: park sr. Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439693 Clinical Trial.
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, Park SR. Lee KW, et al. Among authors: park yi, park sr. Cancer Res Treat. 2017 Jul;49(3):706-716. doi: 10.4143/crt.2016.216. Epub 2016 Oct 18. Cancer Res Treat. 2017. PMID: 27764906 Free PMC article. Clinical Trial.
Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S, Park SJ, Ryu MH, Park SR, Ryoo BY, Park YS, Na YS, Lee CW, Lee JK, Kang YK. Seo S, et al. Among authors: park sr, park ys, park sj. Oncotarget. 2017 May 16;8(20):33844-33854. doi: 10.18632/oncotarget.12953. Oncotarget. 2017. PMID: 27802183 Free PMC article.
Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J, Byeon SJ, Kang YK. Kim JH, et al. Among authors: park sr. Cancer Res Treat. 2018 Apr;50(2):518-529. doi: 10.4143/crt.2017.005. Epub 2017 May 24. Cancer Res Treat. 2018. PMID: 28546521 Free PMC article. Clinical Trial.
699 results